Alex Janin
Health Reporter at The Wall Street Journal
Covering aging, longevity and preventive care for @WSJ. A health reporter with a sweet tooth. Signal: alexjanin.82
Articles
-
1 week ago |
jp.wsj.com | Alex Janin
健康にこだわる一部の米国人は、次に注目すべき抗加齢薬が既に存在しており、数百万人に上る糖尿病患者の薬棚の中にあると考えている。 ジャディアンスやフォシーガなどの商品名で販売され、広く使用されているSGLT2阻害剤は、10年以上も前から2型糖尿病の治療薬として流通している。心不全や腎臓病のような疾患の治療薬としても規制当局から承認されている。Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
-
2 weeks ago |
livemint.com | Alex Janin
The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications. They have also gained regulatory approval to treat conditions like heart failure and kidney disease. Recently, though, the drugs have emerged as a hot topic on popular health podcasts and Reddit forums for longevity enthusiasts, many of whom don’t suffer from any of those conditions.
-
2 weeks ago |
wsj.com | Alex Janin
Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier for longerSome health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications.
-
2 weeks ago |
wsj.com | Alex Janin
Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications. They have also gained regulatory approval to treat conditions like heart failure and kidney disease.
-
1 month ago |
wsj.com | Alex Janin
Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulationsA government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8Subscribe NowAlready a subscriber? Sign In
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 10K
- Tweets
- 1K
- DMs Open
- Yes
RT @loyalfordogs: Curious about what the future of longevity drugs could look like? Watch our Founder & CEO @celinehalioua's conversion wit…
Today at @WSJ Future of Everything, the future of longevity drugs with with @celinehalioua and @JamesPeyer https://t.co/RMjm7KFVfc
I am deeply proud to call @MoiseNoise a friend and colleague. No journalist wants to be the story. She was brave enough to do what we so often ask of our sources: to share painful, personal experiences—and to put her name behind it.
What happened to me was deeply private, and I HATE talking about it. I only shared it publicly in hopes that it might help someone. The hardest part of this experience has been learning how many other women he hurt after me, in almost the exact same way. 1/5